Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

x of Severity (CDEIS) was observed in the 500 mg QD group compared to placebo (CDEIS decrease of -8.4 vs. -1.1 for placebo, p=0.049). C-reactive protein (CRP) results confirmed the effect of 500 mg QD Traficet-EN. Traficet-EN may offer a new orally available treatment option with a favorable side effect profile to patients with this chronic gastrointestinal disease.

"Targeting the CCR9 chemokine receptor represents a new and highly specific approach to treating patients with Crohn's disease and potentially ulcerative colitis," said Pirow Bekker, M.D., Ph.D., Senior Vice President, Medical and Clinical Affairs of ChemoCentryx. "No cure exists for inflammatory bowel diseases and many patients do not respond to or cannot tolerate current treatment options, including the newer biologics such as anti-Tumor Necrosis Factor (TNF) agents, which need to be injected or infused. There was no evidence of an increased risk of infection with Traficet-EN in PROTECT-1. This safety and efficacy profile may translate into a meaningful treatment option for patients."

"These data highlight a year of unparalleled clinical development progress by the ChemoCentryx team. This is true not only for our CCR9 program, but throughout our entire pipeline," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Traficet-EN results announced today underscore our leadership position in CCR9-based therapeutics for the treatment of inflammatory bowel diseases."

The randomized, placebo-controlled, double-blind PROTECT-1 clinical trial of more than 430 patients is comprised of three discrete phases which allows for evaluation of efficacy and safety of Traficet-EN in inducing a clinical response or remission, as well as maintaining response/remission in Crohn's disease over a combined total of 12 months. The Induction Phase of the study is followed by a four-week, open label 'Active Period', during which all subje
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... 16, 2014   Evana Automation Specialists , a ... and test systems, recently received a contract to provide ... manufacturer. The Evana solution will help error-proof the process ... well as reduce labor. A catheter ... robotic assembly cell. The robot will pick the adapter, ...
(Date:9/16/2014)... ORLANDO, Fla. , Sept. 16, 2014   ... standard in the patient experience at hospitals. The myComfort™ ... , Vestagen,s active barrier fabric that is fluid repellant, ... shown to inhibit the growth of bacteria on the ... the role clothing plays in the chain of transmission. ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2
... (OTC Bulletin Board: ACUR) (the "Company") today announced ... "Agreement"), with an,investor group comprised of Vivo Ventures ... L.P., GCE Holdings LLC and certain individual investors,(the ... Units ("Units") at a price of $1.08 per ...
... 20 Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned ... RLL has received approval from the U.S. Food ... and,Acetaminophen Tablets USP, 7.5 mg/750 mg, 10 mg/500 ... The Office of Generic Drugs, U.S. Food and ...
Cached Medicine Technology:Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate 2Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate 3Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP 2
(Date:9/16/2014)... 16, 2014 CarePoint Health is ... Leigh Montes, MD, has joined our expanded Bariatric ... Hospital. Our system welcomes Dr. Montes to the ... surgical weight loss center, helps patients achieve long-term ... surgery procedures, including Gastric Sleeve, Gastric Bypass, LAP-BAND ...
(Date:9/16/2014)... HealthDay Reporter MONDAY, Sept. 15, 2014 ... can delay a man,s onset of age-related high blood pressure ... pressure naturally increases as people grow older and their arteries ... don,t start drifting toward high blood pressure until their mid-50s. ... early signs of high blood pressure in their mid-40s, researchers ...
(Date:9/16/2014)... discoveries everyday, but that doesn,t mean the findings are ... example, the neonatal mortality rate is 10 times higher ... that applying an inexpensive topical solution of chlorhexidine to ... rate by 24 percent, many Indian parents did not ... not that we don,t have solutions to solve major ...
(Date:9/16/2014)... The Columbia University College of Dental Medicine ... in Diversity (HEED) award from INSIGHT Into Diversity ... higher education. As a recipient of the annual ... universities that demonstrate an outstanding commitment to diversity ... other recipients in INSIGHT Into Diversity magazine,s November ...
(Date:9/16/2014)... Size is relative, especially to people who tend to ... University Medical Center in the US found that seven ... weighs. People of normal weight make this mistake much ... tend to misjudge their children,s size, as youngsters misjudge ... now at Weill-Cornell Medical College, in a study in ...
Breaking Medicine News(10 mins):Health News:Top Bariatric Surgeon Joins CarePoint Health 2Health News:Top Bariatric Surgeon Joins CarePoint Health 3Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Pairing social networks with social motives to close the science gap 2Health News:Pairing social networks with social motives to close the science gap 3Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Poor body size judgement can lead to increased tolerance of obesity 2
... , MONDAY, March 21 (HealthDay News) -- A woman,s use ... risk of respiratory problems in her children, according to a ... use of birth control pills may increase the risk of ... said the authors of the new study. The researchers ...
... MONDAY, March 21 (HealthDay News) -- While the majority of ... generally satisfied years later, almost 40 percent are saddled with ... removed, a small, new Belgian study reveals. The finding ... the University of California, San Francisco that suggested gastric bypass ...
... Rockville, Md., March 21, 2011 As part of ... Pharmacopeial Convention (USP) is working with the Food and ... (CHPA) to update quality standards for widely used medicines ... an ambitious, long-term effort to assess written (or documentary) ...
... Health Sciences University is enrolling patients in a federally funded ... progression of kidney disease. "The question is, if you ... said Dr. Laura Mulloy, Chief of the GHSU Section of ... Intervention Trial, or SPRINT, funded by the National Institutes of ...
... change the balance of bacteria that naturally live in the ... Brain, Behavior, and Immunity . "These bacteria ... the immune response," said lead researcher Michael Bailey. ... number of gut microorganisms, according to scientists from The Ohio ...
... March, 2011 Alcohol use during pregnancy is common ... and development of exposed offspring. Despite warnings from the ... contemplating pregnancy, a recent survey by the National Birth ... drank alcohol at some time during their pregnancy, with ...
Cached Medicine News:Health News:Moms' Use of 'the Pill' Won't Raise Kids' Asthma Risk: Study 2Health News:40% of Gastric Banding Patients Have Complications 2Health News:40% of Gastric Banding Patients Have Complications 3Health News:40% of Gastric Banding Patients Have Complications 4Health News:Quality standards for widely used medicines strengthened 2Health News:Quality standards for widely used medicines strengthened 3Health News:Study examines whether lower blood pressure reduces kidney disease progression 2Health News:Adolescent offspring of women who drank alcohol during first trimester 2
... Battery Powered Orthopedic Systems., ,The PowerPro® ... to the Hall® Surgical line of powered ... the first and only software controlled battery ... is a full-function orthopedic power system specifically ...
... Brasseler USAs Large Bone Power System is ... new technological advancements. The truly innovative design ... pack, which is comprised of the battery, ... contains only mechanical components, which provides a ...
... is a type I collagen implant designed ... or loss of meniscus tissue, typically through ... purpose of the CMI is to assist ... a more vigorous lifestyle, while forestalling or ...
... OBIs proprietary PolyGraft® material technology which ... that is both biologically friendly and ... of polylactide-co-glycolide, calcium sulfate and polyglycolide ... fabricated into products such as granules, ...
Medicine Products: